Netherlands Working Group on Immunotherapy of Oncology Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2011
NCT01408004
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Renal Cell (Phase 2)

Kidney Neoplasms (Phase 2)

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4